Ignite Creation Date:
2024-05-06 @ 7:01 PM
Last Modification Date:
2024-10-26 @ 2:59 PM
Study NCT ID:
NCT05868226
Status:
RECRUITING
Last Update Posted:
2023-11-18
First Post:
2022-04-22
Brief Title:
PRE-I-SPY Phase IIb Oncology Platform Program
Sponsor:
QuantumLeap Healthcare Collaborative
Organization:
QuantumLeap Healthcare Collaborative
Conditions & Keywords Data
Conditions:
| Name |
|---|
| PR-positive Breast Cancer |
| HER2-positive Breast Cancer |
| Metastatic Cancer |
| Metastatic Breast Cancer |
| Metastatic |
| HER2-positive Metastatic Breast Cancer |
| HER2 Mutation-Related Tumors |
| HER-2 Protein Overexpression |
| HER2-negative Breast Cancer |
| Triple Negative Breast Cancer |
| HR Positive |
| Hormone Receptor-positive Breast Cancer |
| Estrogen Receptor Positive Tumor |
| Progesterone Receptor-positive Breast Cancer |
| Hormone Receptor Negative Breast Carcinoma |
| Solid Tumor |
| Solid Tumor Adult |
| Solid Carcinoma |
| HER2 Low Breast Cancer |
| HER2 Low Breast Carcinoma |
| ER Positive Breast Cancer |
Keywords:
| Name | View |
|---|---|
| PRE3 | View |
| I-SPY Trials | View |
| Quantum Leap Healthcare Collaborative | View |
| QLHC | View |
| I-SPY | View |
| I-SPY2 | View |
| I-SPY1 | View |
| PRE-ISPY | View |
| PRE-I-SPY | View |
| I-SPY Phase 1 | View |
| I-SPY Phase 1b | View |
| I-SPY-P1 | View |
| ISPY | View |
| ISPYP1 | View |
| I-SPY Phase 1 Platform | View |
| ISPY2 | View |
| ISPY1 | View |
| Phase 1 Platform | View |
| Phase 1 Oncology Platform | View |
| T-DXd naive | View |
| PRE1 | View |
| PRE2 | View |